143 Participants Needed

Letermovir for Preventing Infection After Stem Cell Transplant in Blood Cancer

Recruiting at 18 trial locations
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 2 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This phase III trial determines whether taking prophylactic letermovir will reduce the likelihood of infection with cytomegalovirus (CMV) in children and adolescents after stem cell transplant. The treatments used to prepare for HCT reduce the body's natural infection-fighting ability and increase the likelihood of an infection with a virus called cytomegalovirus. "Prophylaxis" means to take a drug to prevent a disease or side effect. Letermovir is an antiviral drug that stops cytomegalovirus from multiplying and may prevent cytomegalovirus infection and make the disease less severe.

Will I have to stop taking my current medications?

The trial requires that certain medications be stopped at least 14 days before starting the study. These include pimozide, ergot alkaloids, and specific statins if you are taking cyclosporine. Check with the trial team to see if your current medications are on this list.

Is Letermovir safe for humans?

Letermovir has been approved in several countries, including the USA, Canada, and Japan, for preventing cytomegalovirus infection in patients who have had a stem cell transplant. Studies, including a phase III trial, have shown no significant link between the drug's exposure and adverse events, supporting its safety at recommended doses.12345

How is the drug Letermovir unique for preventing infection after stem cell transplant in blood cancer?

Letermovir is unique because it specifically targets and prevents infections caused by cytomegalovirus (CMV), a common and potentially serious virus in patients undergoing stem cell transplants, whereas other treatments often focus on maintaining remission or preventing relapse of the cancer itself.678910

Who Is on the Research Team?

CW

Caitlin W Elgarten

Principal Investigator

Children's Oncology Group

Are You a Good Fit for This Trial?

This trial is for children and teens (2-18 years old) who weigh at least 18 kg, are CMV sero-positive, and are planning to have a stem cell transplant. They must be healthy enough for the procedure (Lansky/Karnofsky scores > 50), not need dialysis, and have acceptable liver function tests.

Inclusion Criteria

Patient must be CMV sero-positive (i.e., recipient CMV immunoglobulin G positive)
I am between 2 and 17 years old.
My kidneys work well enough and I'm not on dialysis.
See 5 more

Exclusion Criteria

Hypersensitivity to letermovir or any component of the formulation
I cannot take letermovir by mouth.
All patients and/or their parents or legal guardians must sign a written informed consent
See 8 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive letermovir orally or intravenously once daily starting on day +1 post-transplant for 14 weeks

14 weeks
Weekly visits for blood sample collection

Follow-up

Participants are monitored for CMV infection and other outcomes post-treatment

48 weeks
Every 2 weeks until week 24, then at weeks 32, 40, and 52

What Are the Treatments Tested in This Trial?

Interventions

  • Letermovir
Trial Overview The study is testing if Letermovir can prevent cytomegalovirus infection in pediatric patients after a stem cell transplant. The drug aims to stop the virus from multiplying, potentially preventing or lessening the severity of infections.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: ARM I (Letermovir prophylaxis)Experimental Treatment2 Interventions
Group II: ARM II (No prophylaxis)Active Control1 Intervention

Letermovir is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Prevymis for:
🇪🇺
Approved in European Union as Prevymis for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Children's Oncology Group

Lead Sponsor

Trials
467
Recruited
241,000+

Published Research Related to This Trial

Letermovir (Prevymis™) is an effective prophylactic treatment for preventing cytomegalovirus (CMV) infection and disease in adult patients who are CMV-seropositive and have received an allogeneic hematopoietic stem cell transplant, with approvals in Canada and the USA.
The drug works by inhibiting the CMV DNA terminase complex and has received positive regulatory feedback in Europe, indicating its potential for broader international use.
Letermovir: First Global Approval.Kim, ES.[2019]
In a retrospective analysis of patients who underwent allogeneic hematopoietic stem cell transplantation, letermovir prophylaxis significantly reduced the incidence of clinically significant CMV infections (30.2% vs. 71.6% in the control group) within 100 days, indicating its efficacy in preventing CMV reactivation.
The study also found that letermovir prophylaxis was associated with lower non-relapse mortality (4.7% vs. 19.8% at day 500), and identified that receiving a transplant from a CMV seronegative donor to a seropositive recipient increased the risk of CMV infection even with letermovir treatment.
Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation.Mizuno, K., Sakurai, M., Kato, J., et al.[2022]
In a 6-year post-marketing surveillance study involving 461 Japanese patients who received allogenic hematopoietic stem-cell transplantation, letermovir was found to be safe, with 13.9% experiencing adverse drug reactions, primarily renal impairment and nausea.
The effectiveness of letermovir for CMV prophylaxis was confirmed, with CMV antigen positivity rates of 21.2% at Week 14 and 37.5% at Week 24 after transplantation, indicating its role in reducing CMV infection risk in this patient population.
Safety and Effectiveness of Letermovir in Allogenic Hematopoietic Stem Cell Transplantation Recipients: Interim Report of Post-marketing Surveillance in Japan.Hiraishi, I., Ueno, R., Watanabe, A., et al.[2022]

Citations

Letermovir: First Global Approval. [2019]
Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation. [2022]
Safety and Effectiveness of Letermovir in Allogenic Hematopoietic Stem Cell Transplantation Recipients: Interim Report of Post-marketing Surveillance in Japan. [2022]
Absorption, Metabolism, Distribution, and Excretion of Letermovir. [2022]
Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients. [2022]
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. [2021]
7.Czech Republicpubmed.ncbi.nlm.nih.gov
[Lenalidomide maintenance therapy in patients with multiple myeloma]. [2019]
FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation. [2023]
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). [2021]
10.United Statespubmed.ncbi.nlm.nih.gov
Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security